company background image

Medlab Clinical ASX:MDC Stock Report

Last Price


Market Cap







29 Sep, 2022


Company Financials +
MDC fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health4/6

MDC Stock Overview

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.

Medlab Clinical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medlab Clinical
Historical stock prices
Current Share PriceAU$11.04
52 Week HighAU$30.00
52 Week LowAU$6.45
1 Month Change-16.36%
3 Month Change36.30%
1 Year Change-50.93%
3 Year Change-83.46%
5 Year Change-89.49%
Change since IPO-63.20%

Recent News & Updates

Shareholder Returns

MDCAU BiotechsAU Market

Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -8% over the past year.

Return vs Market: MDC underperformed the Australian Market which returned -12.6% over the past year.

Price Volatility

Is MDC's price volatile compared to industry and market?
MDC volatility
MDC Average Weekly Movement16.0%
Biotechs Industry Average Movement10.4%
Market Average Movement9.6%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market4.2%

Stable Share Price: MDC is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: MDC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

2012n/aSean Hall

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.

Medlab Clinical Fundamentals Summary

How do Medlab Clinical's earnings and revenue compare to its market cap?
MDC fundamental statistics
Market CapAU$25.16m
Earnings (TTM)-AU$8.32m
Revenue (TTM)AU$1.28m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDC income statement (TTM)
Cost of RevenueAU$336.29k
Gross ProfitAU$946.14k
Other ExpensesAU$9.27m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-3.64
Gross Margin73.78%
Net Profit Margin-648.93%
Debt/Equity Ratio0%

How did MDC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is MDC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDC?

Other financial metrics that can be useful for relative valuation.

MDC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue16.2x
Enterprise Value/EBITDA-2.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MDC's PS Ratio compare to its peers?

MDC PS Ratio vs Peers
The above table shows the PS ratio for MDC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average20.8x
IMC Immuron
BNO Bionomics
NC6 Nanollose
1AD AdAlta
MDC Medlab Clinical

Price-To-Sales vs Peers: MDC is good value based on its Price-To-Sales Ratio (19.7x) compared to the peer average (20.8x).

Price to Earnings Ratio vs Industry

How does MDC's PE Ratio compare vs other companies in the AU Biotechs Industry?

Price-To-Sales vs Industry: MDC is expensive based on its Price-To-Sales Ratio (19.7x) compared to the Australian Biotechs industry average (19.6x)

Price to Sales Ratio vs Fair Ratio

What is MDC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio19.7x
Fair PS Ratio19.6x

Price-To-Sales vs Fair Ratio: MDC is expensive based on its Price-To-Sales Ratio (19.7x) compared to the estimated Fair Price-To-Sales Ratio (19.6x).

Share Price vs Fair Value

What is the Fair Price of MDC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MDC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDC's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Medlab Clinical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MDC's revenue (51.1% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: MDC's revenue (51.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Medlab Clinical performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MDC is currently unprofitable.

Growing Profit Margin: MDC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.

Accelerating Growth: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.2%).

Return on Equity

High ROE: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Medlab Clinical's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MDC's short term assets (A$9.2M) exceed its short term liabilities (A$2.9M).

Long Term Liabilities: MDC's short term assets (A$9.2M) exceed its long term liabilities (A$740.8K).

Debt to Equity History and Analysis

Debt Level: MDC is debt free.

Reducing Debt: MDC has no debt compared to 5 years ago when its debt to equity ratio was 9.9%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MDC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.7% each year

Discover healthy companies


What is Medlab Clinical current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Medlab Clinical Dividend Yield vs Market
How does Medlab Clinical dividend yield compare to the market?
SegmentDividend Yield
Company (Medlab Clinical)n/a
Market Bottom 25% (AU)2.8%
Market Top 25% (AU)7.2%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (Medlab Clinical)0%

Notable Dividend: Unable to evaluate MDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDC has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Sean Hall





Dr. Sean Michael Hall serves as the Chief Executive Officer at Medlab Clinical Limited and served as its Managing Director. He served as a Managing Director of Medlab Clinical Limited until November 2020....

CEO Compensation Analysis

Sean Hall's Compensation vs Medlab Clinical Earnings
How has Sean Hall's remuneration changed compared to Medlab Clinical's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022AU$574kAU$441k


Mar 31 2022n/an/a


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021AU$677kAU$372k


Mar 31 2021n/an/a


Dec 31 2020n/an/a


Sep 30 2020n/an/a


Jun 30 2020AU$379kAU$300k


Mar 31 2020n/an/a


Dec 31 2019n/an/a


Sep 30 2019n/an/a


Jun 30 2019AU$364kAU$299k


Mar 31 2019n/an/a


Dec 31 2018n/an/a


Sep 30 2018n/an/a


Jun 30 2018AU$328kAU$299k


Mar 31 2018n/an/a


Dec 31 2017n/an/a


Sep 30 2017n/an/a


Jun 30 2017AU$328kAU$299k


Mar 31 2017n/an/a


Dec 31 2016n/an/a


Sep 30 2016n/an/a


Jun 30 2016AU$328kAU$299k


Compensation vs Market: Sean's total compensation ($USD372.17K) is above average for companies of similar size in the Australian market ($USD272.76K).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: MDC's board of directors are considered experienced (8.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: MDC insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

ASX:MDC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Jul 22BuyAU$10,000Sean HallIndividual832.14AU$12.02
12 Apr 22BuyAU$10,000Sean HallIndividual832.14AU$12.02
04 Apr 22BuyAU$10,000Sean HallIndividual732.6AU$13.65
30 Mar 22BuyAU$8,997Sean HallIndividual638.29AU$14.10
04 Nov 21BuyAU$18,000Sean HallIndividual666.67AU$27.00

Ownership Breakdown

What is the ownership structure of MDC?
Owner TypeNumber of SharesOwnership Percentage
Private Companies164,0327.2%
Individual Insiders611,45026.8%
General Public1,283,51856.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 16 shareholders own 43.79% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Sean Hall
392,373A$4.3m0.21%no data
Farjoy Pty Ltd
Drew Townsend
107,570A$1.2m0%no data
Fit Investments Pty. Ltd.
82,230A$907.8k0%no data
Richard Albarran
37,038A$408.9k0%no data
United Trolley Collections P/L
32,970A$364.0k0%no data
Michael Hall
23,820A$263.0k0%no data
David Rutolo
20,000A$220.8k0%no data
Villamagna Inc
20,000A$220.8k0%no data
Netwealth Investments Ltd.
18,839A$208.0k-4.82%no data
Acron Holdings Pty Limited
16,181A$178.6k0.01%no data
Elizabeth Jones
14,910A$164.6k0%no data
D.J Fairfull Pty Ltd
12,651A$139.7k0.01%no data
Fu Xiaodan
11,902A$131.4k0%no data
Ian Curtinsmith
3,096A$34.2k0%no data
Luis Vitetta
741A$8.2k0%no data

Company Information

Medlab Clinical Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Medlab Clinical Limited
  • Ticker: MDC
  • Exchange: ASX
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$25.164m
  • Shares outstanding: 2.28m
  • Website:


  • Medlab Clinical Limited
  • Building A
  • Unit A5 – A6, Botany Quarter
  • Botany
  • New South Wales
  • 2019
  • Australia


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDCASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJul 2015
MDCCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJul 2015
MDBB.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2015

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/29 00:00
Annual Earnings2022/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.